metricas
covid
Annals of Hepatology Camrelizumab combined with transcatheter arterial chemoembolization and sorafeni...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study
Xiumei Jianga,1, Pan Wangb,c,1, Ke Suc,d,1, Han Lic, Hao Chic, Fei Wange, Yu Liua,
Corresponding author
cqmuliuyu@163.com

Corresponding authors.
, Ke Xua,
Corresponding author
nsmcxuke@163.com

Corresponding authors.
a Department of Oncology, Chongqing General Hospital, Chongqing, 401147, China
b Clinical Skills Center, The Affliated Hospital of Southwest Medical University, Luzhou, 646000, China
c Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China
d Department of Radiation Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100000, China
e Department of General Surgery, Luxian People's Hospital, Luzhou, 646100, China
Read
1725
Times
was read the article
385
Total PDF
1340
Total HTML
Share statistics
Article information
ISSN: 16652681
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 12 40 11 51
2025 11 214 62 276
2025 10 108 55 163
2025 9 103 46 149
2025 8 126 42 168
2025 7 175 30 205
2025 6 89 51 140
2025 5 58 5 63
2025 4 61 13 74
2025 3 58 11 69
2025 2 37 6 43
2025 1 68 6 74
2024 12 49 5 54
2024 11 53 6 59
2024 10 64 18 82
2024 9 37 18 55
Show all

Follow this link to access the full text of the article